Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for treating pulmonary disease using inter-[alpha] inhibitor proteins

A technology for pneumonia and pneumonia symptoms, applied in the field of acute lung disease treatment, can solve the problem of ARDS mortality rate exceeding 40%

Pending Publication Date: 2019-05-21
POROTHERA BIOLOGY
View PDF16 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite significant advances in critical care management, mortality in ARDS remains over 40%

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0172] Example 1. Treatment of Pneumonia Patients

[0173] A 65-year-old man presented to the hospital. The patient explained that he was not breathing well, was short and rapid, and appeared to be gasping for air. The patient further complained of severe chest pain and coughing. On examination, the clinician noted weakened vital signs, fever, and bluish nail beds. The clinician also auscultates (eg, using a stethoscope) the patient's lungs as the patient inhales and exhales. Clinicians hear crackles and other noises in the lungs. At this point, the patient was admitted with suspected pneumonia, was given antibiotics, and then sent for a chest X-ray. After reviewing the patient's X-rays, clinicians made a tentative diagnosis of pneumonia. Clinicians can also order lab tests, such as blood cultures, which can take up to 48 hours for the first readout and up to five days for the full readout. The level of IαIp (eg, IαI and / or PαI) in a patient-derived biological sample (eg...

example 2

[0175] Example 2. Treatment of patients with chronic obstructive pulmonary disease

[0176] A 60-year-old female patient with chronic obstructive pulmonary disease was scheduled for lung transplantation. In preparation for her surgery, the patient was prescribed IαIp (eg IαI and / or PαI) at 5 mg / kg twice daily for one week prior to surgery.

example 3

[0177] Example 3. Treatment of Patients with Acute Respiratory Distress Syndrome

[0178] A 65-year-old man with aspiration of gastric contents was admitted to the hospital with weakened vital signs. Upon examination, clinicians noted that the patient had extreme shortness of breath, dyspnea, cough, and fever. The clinician ordered a chest x-ray, and imaging of the patient's chest revealed extensive bilateral infiltrates. The patient was diagnosed with acute respiratory distress syndrome (ARDS) by measuring the patient's PaO 2 / FiO 2 Confirmed by additional laboratory testing with levels <200 mmHg.

[0179] A therapeutically effective dose of IαIp (eg, IαI and / or PαI) is administered to the patient. An effective dose administered intravenously to a patient is 1 mg / kg to 50 mg / kg, preferably 5 mg / kg to 15 mg / kg (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 mg / kg ). At the beginning of treatment, the composition is administered to the patient one or more times every 1, 2,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention features methods for treating or preventing pulmonary diseases, including acute respiratory distress syndrome (ARDS) and pneumonia, in a subject in need thereof that involve administering to the subject inter-[alpha] inhibitor proteins (l[alpha]lps), including, e.g., inter-alpha inhibitor (l[alpha]l) and / or pre-alpha inhibitor (P[alpha]l).

Description

technical field [0001] The present invention relates to the treatment of acute lung diseases, including acute respiratory distress syndrome (ARDS) and pneumonia. Background technique [0002] Acute respiratory distress syndrome (ARDS) is a fatal disease characterized by acute lung injury leading to pulmonary edema and respiratory failure. Patients who have experienced trauma, haemorrhage, severe pneumonia, influenza, and / or sepsis are at risk of developing ARDS. Despite major advances in critical care management, the mortality rate of ARDS remains over 40%. It is estimated that more than 100,000 people in the United States die each year from complications of ARDS. [0003] Pneumonia is a common but serious disease characterized by inflammation of the lungs, usually caused by a lung infection. There are more than 450 million reported cases of pneumonia and an estimated 4 million deaths from pneumonia each year. Pneumonia is particularly severe in children, the elderly, an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/57
CPCA61K38/55A61K45/06A61P11/00A61P31/04A61K9/0019A61K38/57C07K14/811
Inventor 林佑彬D.斯佩罗R.安德鲁斯
Owner POROTHERA BIOLOGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com